York Capital Management Global Advisors LLC acquired a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 276,882 shares of the medical instruments supplier’s stock, valued at approximately $17,953,000. York Capital Management Global Advisors LLC owned about 0.12% of DENTSPLY SIRONA at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of DENTSPLY SIRONA by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 22,728,062 shares of the medical instruments supplier’s stock worth $1,473,688,000 after purchasing an additional 562,993 shares during the last quarter. BlackRock Inc. boosted its stake in shares of DENTSPLY SIRONA by 3,103.7% during the 1st quarter. BlackRock Inc. now owns 13,891,329 shares of the medical instruments supplier’s stock worth $867,376,000 after purchasing an additional 13,457,730 shares during the last quarter. State Street Corp boosted its stake in shares of DENTSPLY SIRONA by 0.4% during the 1st quarter. State Street Corp now owns 9,931,689 shares of the medical instruments supplier’s stock worth $620,136,000 after purchasing an additional 36,012 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of DENTSPLY SIRONA by 22.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,474,432 shares of the medical instruments supplier’s stock worth $419,802,000 after purchasing an additional 1,181,547 shares during the last quarter. Finally, Veritas Asset Management LLP boosted its stake in shares of DENTSPLY SIRONA by 2.6% during the 2nd quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock worth $402,083,000 after purchasing an additional 157,616 shares during the last quarter. 93.87% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have issued reports on XRAY shares. Zacks Investment Research raised shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a research note on Thursday, July 13th. BidaskClub cut shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. HC Wainwright started coverage on shares of DENTSPLY SIRONA in a research note on Tuesday, July 11th. They set a “buy” rating and a $74.00 price target on the stock. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $75.00 price target (up from $67.00) on shares of DENTSPLY SIRONA in a research note on Thursday, July 13th. Finally, Jefferies Group LLC decreased their price target on shares of DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating on the stock in a research note on Wednesday, August 23rd. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $65.89.

Shares of DENTSPLY SIRONA Inc. (NASDAQ XRAY) traded down 0.22% on Friday, hitting $58.85. 1,853,319 shares of the stock traded hands. The company’s 50 day moving average is $57.06 and its 200 day moving average is $61.28. The stock’s market cap is $13.51 billion. DENTSPLY SIRONA Inc. has a one year low of $52.54 and a one year high of $65.68.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.65. DENTSPLY SIRONA had a positive return on equity of 7.24% and a negative net margin of 20.57%. The company had revenue of $992.70 million for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the previous year, the business posted $0.76 EPS. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, equities analysts forecast that DENTSPLY SIRONA Inc. will post $2.68 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/06/york-capital-management-global-advisors-llc-invests-17-95-million-in-dentsply-sirona-inc-xray-stock.html.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Stock Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related stocks with our FREE daily email newsletter.